Widlitz AC - Search Results

1

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.

Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ. Tapson VF, et al. Among authors: widlitz ac. Chest. 2006 Mar;129(3):683-8. doi: 10.1378/chest.129.3.683. Chest. 2006. PMID: 16537868 Clinical Trial.

2

Practical aspects of continuous intravenous treprostinil therapy.

Widlitz AC, McDevitt S, Ward GR, Krichman A. Widlitz AC, et al. Crit Care Nurse. 2007 Apr;27(2):41-2, 44-5, 47-50; quiz 51. Crit Care Nurse. 2007. PMID: 17389412 Review. No abstract available.

3

Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.

Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, Rosenzweig EB, Barst RJ. Kawut SM, et al. Among authors: widlitz ac. Pulm Pharmacol Ther. 2006;19(5):370-4. doi: 10.1016/j.pupt.2006.01.001. Epub 2006 Feb 17. Pulm Pharmacol Ther. 2006. PMID: 16483811

4

Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.

Widlitz AC, Barst RJ, Horn EM. Widlitz AC, et al. Expert Rev Cardiovasc Ther. 2005 Nov;3(6):985-91. doi: 10.1586/14779072.3.6.985. Expert Rev Cardiovasc Ther. 2005. PMID: 16292989 Review.

5

von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension.

Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. Kawut SM, et al. Among authors: widlitz ac. Chest. 2005 Oct;128(4):2355-62. doi: 10.1378/chest.128.4.2355. Chest. 2005. PMID: 16236894

6

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ. Gomberg-Maitland M, et al. Among authors: widlitz ac. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-9. doi: 10.1164/rccm.200505-766OC. Epub 2005 Sep 8. Am J Respir Crit Care Med. 2005. PMID: 16151039 Clinical Trial.

7

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.

Horn EM, Widlitz AC, Barst RJ. Horn EM, et al. Among authors: widlitz ac. Expert Opin Investig Drugs. 2004 Nov;13(11):1483-92. doi: 10.1517/13543784.13.11.1483. Expert Opin Investig Drugs. 2004. PMID: 15500395

8

Pulmonary arterial hypertension in children.

Rosenzweig EB, Widlitz AC, Barst RJ. Rosenzweig EB, et al. Among authors: widlitz ac. Pediatr Pulmonol. 2004 Jul;38(1):2-22. doi: 10.1002/ppul.20051. Pediatr Pulmonol. 2004. PMID: 15170869 Review.

9

Outcomes in children with idiopathic pulmonary arterial hypertension.

Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Yung D, et al. Among authors: widlitz ac. Circulation. 2004 Aug 10;110(6):660-5. doi: 10.1161/01.CIR.0000138104.83366.E9. Epub 2004 Aug 2. Circulation. 2004. PMID: 15289375

10

Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.

Tapson VF, McLaughlin VV, Gomberg-Maitland M, Widlitz AC, Krichman AD, Laliberte KJ, Zaccardelli DS, Barst RJ. Tapson VF, et al. Among authors: widlitz ac. J Vasc Access. 2006 Jul-Sep;7(3):112-7. doi: 10.1177/112972980600700304. J Vasc Access. 2006. PMID: 17019662 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results